Shin Nippon Biomedical Laboratories, Ltd.

OTCPK:SBLO.F Stock Report

Market Cap: US$334.0m

Shin Nippon Biomedical Laboratories Past Earnings Performance

Past criteria checks 1/6

Shin Nippon Biomedical Laboratories's earnings have been declining at an average annual rate of -7.1%, while the Life Sciences industry saw earnings declining at 3.7% annually. Revenues have been growing at an average rate of 16.2% per year. Shin Nippon Biomedical Laboratories's return on equity is 10.4%, and it has net margins of 14%.

Key information

-7.11%

Earnings growth rate

-7.11%

EPS growth rate

Life Sciences Industry Growth21.51%
Revenue growth rate16.17%
Return on equity10.43%
Net Margin14.04%
Next Earnings Update05 Aug 2026

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shin Nippon Biomedical Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:SBLO.F Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2632,5244,56610,7732,400
31 Dec 2531,3743,9909,1002,218
30 Sep 2534,6714,65411,5542,217
30 Jun 2533,3425,0639,2482,218
31 Mar 2532,4134,92411,3692,217
31 Dec 2430,7014,94211,3130
30 Sep 2427,0743,89610,5581,741
30 Jun 2426,1954,2809,7290
31 Mar 2426,4505,5318,1181,741
31 Dec 2326,7035,5039,033683
30 Sep 2326,6264,6077,806683
30 Jun 2326,8485,4897,520683
31 Mar 2325,0906,0606,894683
31 Dec 2221,1736,2316,050425
30 Sep 2220,1358,0435,648425
30 Jun 2218,7537,2455,178425
31 Mar 2217,7487,1274,908425
31 Dec 2117,6367,4324,803392
30 Sep 2116,0686,0254,566392
30 Jun 2114,9784,8444,417392
31 Mar 2115,1103,6614,482392
31 Dec 2014,9102,4214,574400
30 Sep 2015,1752,8124,692400
30 Jun 2015,0043,2344,764400
31 Mar 2014,5612,5504,840400
31 Dec 1913,4971,9904,308339
30 Sep 1913,1671,9154,175339
30 Jun 1914,6761,5244,656339
31 Mar 1915,6581,9504,865339
31 Dec 1817,337-494,996518
30 Sep 1817,928-9935,251518
30 Jun 1816,937-2,5665,016518
31 Mar 1816,600-3,5555,139518
31 Dec 1717,186-1,0725,081600
30 Sep 1717,7143275,177600
30 Jun 1717,2302605,250600
31 Mar 1717,244-9155,301600
31 Dec 1615,880-1,8215,157815
30 Sep 1615,269-1,2735,282815
30 Jun 1614,922-1,4755,390815
31 Mar 1614,7502,6465,496815
31 Dec 1515,6372,0605,550739
30 Sep 1516,3444015,554739

Quality Earnings: SBLO.F has high quality earnings.

Growing Profit Margin: SBLO.F's current net profit margins (14%) are lower than last year (15.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SBLO.F's earnings have declined by 7.1% per year over the past 5 years.

Accelerating Growth: SBLO.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SBLO.F had negative earnings growth (-7.3%) over the past year, making it difficult to compare to the Life Sciences industry average (12.6%).

Return on Equity

High ROE: SBLO.F's Return on Equity (10.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/01 07:56
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shin Nippon Biomedical Laboratories, Ltd. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuki TsukamotoBofA Global Research
Akitada IwasaDaiwa Securities Co. Ltd.
Stephen BarkerJefferies LLC